Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Bladder Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Targeted Therapies in Oncology - 2014
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
2013
|
2012
January 2014
March 2014
May 2014
July 2014
September 2014
November 2014
JTT Articles
Participating Practices Commend CMS for OCM Changes
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
>> View Peer-Reviewed Articles
Most Popular
FDA Grants Fast Track and Orphan Drug Designations to Novel Agent Targeting P53 in MDS
Levy Works Through Therapy Options in Patients With NSCLC Who Lack a Driver Mutation
Immunotherapy and TKI Combinations Are Emerging as Standard of Care in Advanced RCC
TMB Shows Promise as Biomarker for Durvalumab Activity in NSCLC
